`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`APOTEX CORP.
`Petitioner
`
`v.
`
`ALCON RESEARCH, LTD.
`Patent Owner
`
`Case IPR2013-00428
`Patent No. 8,268,299
`
`
`JOINT MOTION TO TERMINATE PROCEEDING
`PURSUANT TO 35 U.S.C. § 317
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2013-00428
`U.S. Patent No. 8,268,299
`
`
`
`Pursuant to 35 U.S.C. § 317 and 37 C.F.R. § 42.74, and pursuant to the
`
`
`
`
`
`
`
`
`
`authorization to file this motion provided by the Board during a conference call
`
`with the parties on July 10, 2014, Petitioner Apotex Corp. (“Apotex”) and Patent
`
`Owner Alcon Research, Ltd. (“Alcon”) jointly request the termination of this inter
`
`partes review of U.S. Patent No. 8,268,299.
`
`The parties have settled their dispute and executed a settlement agreement to
`
`terminate this inter partes review and the parties’ co-pending inter partes review
`
`proceedings 2013-00429 and 2013-00430.
`
`The parties’ settlement agreement has been made in writing, and a true and
`
`correct copy is being filed concurrently herewith as Exhibit 1020. The parties are
`
`also filing concurrently herewith a joint request to treat the settlement agreement as
`
`business confidential information and keep it separate from the files of the IPR and
`
`the involved patent pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(b).
`
`Termination of this inter partes review is proper under 35 U.S.C. § 317(a)
`
`because the Board has not yet decided the merits of the proceeding. Indeed, the
`
`briefing and discovery process in this proceeding has not yet been completed.
`
`Alcon has filed a Patent Owner’s Response to the Petition, but Alcon’s declarants
`
`have not been deposed, and Apotex has not filed a Reply or any evidence in Reply.
`
`Alcon did not file a Motion to Amend and thus no such motion is pending.
`
`
`
`1
`
`
`
`Case IPR2013-00428
`U.S. Patent No. 8,268,299
`
`
`
`
`
`
`
`
`
`
`No other party’s rights will be prejudiced by the termination of this inter
`
`partes review. While there is no litigation pending between Alcon and Apotex
`
`relating to the patent that is the subject of this inter partes review, there is pending
`
`litigation relating to this patent between Alcon and other parties in the following
`
`actions: (1) Alcon Research, Ltd. v. Mylan Pharmaceuticals Inc. & Mylan Inc., No.
`
`1:13-cv-01332 (SLR) (D. Del.), (2) Alcon Research, Ltd. v. Wockhardt Ltd.,
`
`Wockhardt Bio AG, & Wockhardt USA, LLC, No. 1:13-cv-02040 (SLR) (D. Del.),
`
`(3) Alcon Research, Ltd. v. Micro Labs Ltd. & Micro Labs USA Inc., No. 1:14-cv-
`
`00014 (SLR) (D. Del.), and (4) Alcon Research, Ltd. v. Watson Labs., Inc.,
`
`Actavis, Inc. and Actavis Pharma, Inc., No. 1:14-cv-00647 (SLR) (D. Del.). Each
`
`of these litigations is at an early stage. The Mylan action is the fact discovery
`
`period. The Wockhardt action is also in the fact discovery period, albeit at an
`
`earlier stage than the Mylan action. The Micro action has been stayed pending the
`
`outcome of the Mylan or Wockhardt actions. The Watson action has just begun, as
`
`Watson has not yet filed an Answer. None of these other parties’ rights will be
`
`impacted by the termination of this inter partes review.
`
`There are no other proceedings pending before the Patent and Trademark
`
`Office relating to the patent at issue in this inter partes review.
`
`
`
`2
`
`
`
`Case IPR2013-00428
`U.S. Patent No. 8,268,299
`
`
`
`
`
`
`
`
`
`
`Accordingly, Apotex and Alcon respectfully request that this inter partes
`
` Respectfully submitted,
`
`/Eldora L. Ellison/
`Eldora L. Ellison, Ph.D.
`Reg. No. 39,967
`Sterne, Kessler, Goldstein & Fox
`P.L.L.C.
`1100 New York Avenue, N.W.
`Washington, DC 20005
`Phone: 202-371-2600
`1877177.1
`
`
`
`
`review proceeding be terminated.
`
`Dated: July 14, 2014
`
`
`
`/Stanley E. Fisher/
`Stanley E. Fisher
`Reg. No. 55,820
`Williams & Connolly LLP
`725 Twelfth Street NW
`Washington, D.C. 20005
`Phone: 202-434-5289
`
`
`
`
`3
`
`
`
`
`
`CERTIFICATE OF SERVICE (37 C.F.R. §§ 42.6(e))
`
`
`
`The undersigned hereby certifies that a copy of the foregoing “Joint Motion
`
`to Terminate Proceeding Pursuant to 35 U.S.C. § 317,” along with Exhibit 1020,
`
`were served in their entirety on July 14, 2014, via email upon the following
`
`counsel of record for the Patent Owner:
`
`
`
`
`
`
`
`
`
`
`
`
`Stanley E. Fisher
`
`David M. Krinsky
`
`Adam L. Perlman
`
`Dov P. Grossman
`Christopher J. Mandernach
`David M. Horniak
`
`Barry L. Copeland
`
`
`
`
`
`
`
`sfisher@wc.com
`dkrinsky@wc.com
`aperlman@wc.com
`dgrossman@wc.com
`cmandernach@wc.com
`dhorniak@wc.com
`barry.copeland@alcon.com
`patent.docketing@alcon.com
`
`
`
`
` STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`
` /Eldora L. Ellison/
` Eldora L. Ellison, Ph.D.
`Date: July 14, 2014
` Lead Attorney for Petitioner Apotex Corp.
`
`
`
`
`
`1100 New York Avenue, N.W. Registration No. 39,967
`Washington, D.C.20005-3934
`(202) 371-2600